MEDI 578

Drug Profile

MEDI 578

Alternative Names: Anti-NGF monoclonal antibody (MEDI-578); MEDI-578

Latest Information Update: 09 Aug 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Musculoskeletal pain

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-I for Musculoskeletal pain in United Kingdom (IV)
  • 13 Jul 2010 Suspended - Phase-I for Musculoskeletal pain (in osteoarthritis patients) in United Kingdom (IV)
  • 28 Feb 2010 Phase-I clinical trials in Musculoskeletal pain (in osteoarthritis patients) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top